Document Detail


Regulation of ingestive behaviors in the rat by GSK1521498, a novel mu-opioid receptor-selective inverse agonist.
MedLine Citation:
PMID:  21712426     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Mu opioid receptor (MOR) agonism induces palatable food consumption principally through the modulation of rewarding properties of food. GSK1521498, (N-{[3,5-difluoro-3'-(1H-1,2,4-triazol-3-yl)-4-biphenylyl]methyl}-2,3-dihydro-1H-inden-2-amine phosphate (1:1), is a novel opioid receptor inverse agonist that, based on in vitro affinity assays, is greater than 10-fold or 50-fold selective for human or rat MOR, respectively, compared with kappa opioid receptors (KOR) and delta opioid receptors (DOR). Similarly, preferential MOR occupancy versus KOR and DOR was observed by autoradiography in brain slices from Long Evans rats dosed orally with the drug. GSK1521498 suppressed nocturnal food consumption of standard or palatable chow in lean and diet-induced obese (DIO) Long Evans rats. Both the dose-response relationship and time course of efficacy in lean rats fed palatable chow correlated with mu receptor occupancy and the plasma concentration profile of the drug. Chronic oral administration of GSK1521498 induced body weight loss in DIO rats which was comprised of fat mass reduction. The reduction in body weight was equivalent to the cumulative reduction in food consumption, thus, the effect of GSK1521498 on body weight is related to inhibition of food consumption. GSK1521498 suppressed the preference for sucrose-containing solutions in lean rats. In operant response models also using lean rats, GSK1521498 reduced the reinforcement efficacy of palatable food reward and enhanced satiety. In conclusion, GSK1521498 is a potent, MOR-selective inverse agonist that modulates hedonic aspects of ingestion and, therefore, could represent a pharmacological treatment for obesity and binge-eating disorders.
Authors:
Diane M Ignar; Aaron S Goetz; Kimberly Nichols Noble; Luz Helena Carballo; Andrea E Stroup; Julie C Fisher; Joyce A Boucheron; Tracy A Brainard; Andrew L Larkin; Andrea H Epperly; Todd W Shearer; Scott D Sorensen; Jason D Speake; Jonathan D Hommel
Related Documents :
7171056 - Use of zyderm in the aging face.
16049896 - Applications of aminolevulinic acid-based photodynamic therapy in cosmetic facial plast...
19067576 - Analysis of the interactions of a cationic surfactant (lauric arginate) with an anionic...
13130436 - Melatonin production accompanies arousal from daily torpor in siberian hamsters.
23355536 - Control of iron deficiency anemia in low- and middle-income countries.
24824016 - European children's sugar intake on weekdays versus weekends: the idefics study.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-6-28
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  -     ISSN:  1521-0103     ISO Abbreviation:  -     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-6-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
GlaxoSmithKline.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine s...
Next Document:  Detection of prostate cancer with three-dimensional transrectal ultrasound: correlation with biopsy ...